The company reported preliminary full-year 2018 results and set expectations for a solid year of growth in 2019.
The company's lead drug candidate got thrown into a whirlwind of uncertainty.
Two well-managed renewable energy businesses are not getting much love from Wall Street right now, but the high-yield stocks are great long-term buys.
The pharma company reported positive results from an important phase 3 trial.
The paper company recovered after an awful December and then proved Wall Street wrong with full-year 2018 operating results.
One of America's largest electric utilities has committed to generating all of its electricity from zero-carbon sources by 2050. Will peers follow?
Wall Street soured on this water utility after it announced a massive acquisition in a new industry, but that could change when full-year 2018 earnings are reported.
The group rebounded after a terrible end to 2018, but each has big plans for the year ahead.
Also, never buy a penny stock.
The life sciences hardware provider reported full-year 2018 earnings results.
The company announced fiscal first-quarter 2019 financial results and provided an update for the year ahead.
The company announced disappointing early results for a muscular dystrophy gene therapy.
The biodiesel leader rebounded after a sour end to 2018, although investors have plenty to look forward to in the years ahead.
The pharma company is taking the FDA to court over the regulator's insistence on animal testing.
The development-stage LNG exporter announced a widely expected regulatory milestone.
The solar hardware provider turned in a rotten December, but investors have big expectations for 2019.
An expected rule change could create the largest opportunity for ethanol producers in over a decade -- and the timing couldn't be better.
The enzyme leader announced a new and improved technology licensing deal with pharma giant Merck.
The industrial biotech has punched its ticket to the cannabis party, but investors shouldn't get too excited just yet.
The uranium miner and fuel fabricator has battened down the hatches to weather dismal market fundamentals in recent years. Is this the year the efforts pay off?